{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:23:51Z","timestamp":1791908631419,"version":"4.3.4"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"Incyte"},{"name":"Janssen"},{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leo Pharmaceuticals"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sciderm"},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ViDac"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaad.2018.06.056","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T13:08:13Z","timestamp":1531314493000},"page":"43-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":238,"title":["Psoriasis: Which therapy for which patient"],"prefix":"10.1016","volume":"80","author":[{"given":"Shivani B.","family":"Kaushik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.06.056_bib1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/bmj.39202.518484.80","article-title":"Management of psoriasis in pregnancy","volume":"334","author":"Weatherhead","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2018.06.056_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/tera.1420470605","article-title":"Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy","volume":"47","author":"Feldkamp","year":"1993","journal-title":"Teratology"},{"key":"10.1016\/j.jaad.2018.06.056_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","article-title":"Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis","volume":"71","author":"Bar Oz","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2018.06.056_bib4","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1016\/S0041-1345(97)00458-2","article-title":"Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun","volume":"29","author":"Lamarque","year":"1997","journal-title":"Transpl Proc"},{"key":"10.1016\/j.jaad.2018.06.056_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00007890-199502270-00005","article-title":"Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients","volume":"59","author":"Armenti","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2018.06.056_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/tera.1092","article-title":"Pregnancy outcome post renal transplantation","volume":"65","author":"Sgro","year":"2002","journal-title":"Teratology"},{"key":"10.1016\/j.jaad.2018.06.056_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00147-004-0781-9","article-title":"Outcome of pregnancy after organ transplantation: a retrospective survey in Italy","volume":"17","author":"Miniero","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaad.2018.06.056_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archderm.1991.01680030152030","article-title":"Psoriasis, cyclosporine, and pregnancy","volume":"127","author":"Wright","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archderm.142.10.1373","article-title":"Cyclosporine resolves generalized pustular psoriasis of pregnancy","volume":"142","author":"Kapoor","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2230.2005.01869.x","article-title":"Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone","volume":"30","author":"Edmonds","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1046\/j.1365-2133.2000.03396.x","article-title":"Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A","volume":"142","author":"Finch","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib12","first-page":"1197","article-title":"Cyclosporin and pregnancy","volume":"140","author":"Raddadi","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2018.06.056_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2018.06.056_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","article-title":"Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn","volume":"4","author":"Vasiliauskas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib17","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","article-title":"Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding","volume":"49","author":"Berthelsen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2018.06.056_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2015.07.004","article-title":"Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients","volume":"83","author":"Forger","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2018.06.056_bib19","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3899\/jrheum.140189","article-title":"Pregnancy outcomes in subjects exposed to certolizumab pegol","volume":"42","author":"Clowse","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib20","first-page":"1014","article-title":"Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship","volume":"33","author":"Carter","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib22","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3899\/jrheum.090141","article-title":"Was risk properly assessed in Carter, et\u00a0al's safety assessment of tumor necrosis factor antagonists during pregnancy?","volume":"36","author":"Winger","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00393-010-0652-y","article-title":"Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment [in German]","volume":"69","author":"Rump","year":"2010","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jaad.2018.06.056_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2018.06.056_bib26","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00296-012-2433-1","article-title":"Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment","volume":"33","author":"Natsumi","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2018.06.056_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2018.06.056_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gut.2005.065417","article-title":"Adalimumab use in pregnancy","volume":"54","author":"Vesga","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2018.06.056_bib30","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2018.06.056_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00054725-200608000-00020","article-title":"Successful use of adalimumab (Humira) for Crohn's disease in pregnancy","volume":"12","author":"Mishkin","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2018.06.056_bib32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10620-006-9452-2","article-title":"The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy","volume":"51","author":"Coburn","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2018.06.056_bib33","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.22028","article-title":"Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.06.056_bib34","first-page":"1240","article-title":"Treatment of severe psoriasis with ustekinumab during pregnancy","volume":"11","author":"Andrulonis","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jdv.12872","article-title":"Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis","volume":"30","author":"Alsenaid","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3315\/jdcr.2012.1116","article-title":"Spontaneous abortion during ustekinumab therapy","volume":"6","author":"Fotiadou","year":"2012","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.jaad.2018.06.056_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.reprotox.2015.10.008","article-title":"Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys","volume":"58","author":"Clarke","year":"2015","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jaad.2018.06.056_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2015.04.026","article-title":"The new US Food and Drug Administration pregnancy and lactation labeling rules: their impact on clinical practice","volume":"73","author":"Danesh","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/09546634.2014.996515","article-title":"Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry","volume":"26","author":"van Geel","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.06.056_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1525-1470.2008.00629.x","article-title":"Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India","volume":"25","author":"Kaur","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1525-1470.1994.tb00602.x","article-title":"Methotrexate in childhood psoriasis","volume":"11","author":"Kumar","year":"1994","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1525-1470.2005.22122.x","article-title":"Methotrexate for generalized pustular psoriasis in a 2-year-old child","volume":"22","author":"Dogra","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib44","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0190-9622(96)90281-9","article-title":"Cyclosporine in severe childhood atopic dermatitis: a multicenter study","volume":"34","author":"Berth-Jones","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000051694","article-title":"Cyclosporin for atopic dermatitis in children","volume":"203","author":"Harper","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.06.056_bib47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1525-1470.2001.018003246.x","article-title":"Low dose cyclosporin A treatment in generalized pustular psoriasis","volume":"18","author":"Kilic","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2133.1998.02490.x","article-title":"The use of cyclosporin in a child with generalized pustular psoriasis","volume":"139","author":"Alli","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib49","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1346-8138.2006.00201.x","article-title":"Photosensitive psoriasis in a vitiligo patient","volume":"33","author":"Torchia","year":"2006","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib50","first-page":"117","article-title":"Juvenile generalized circinate pustular psoriasis treated with oral cyclosporin A","volume":"11","author":"Wollina","year":"2001","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib51","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1525-1470.2006.00247.x","article-title":"Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin\/narrowband ultraviolet B phototherapy","volume":"23","author":"Kim","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1468-3083.2006.01562.x","article-title":"Cyclosporin A treatment in severe childhood psoriasis","volume":"20","author":"Pereira","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/09546630310012136","article-title":"Cyclosporin in childhood psoriasis","volume":"14","author":"Perrett","year":"2003","journal-title":"J Dermatolog Treat"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2018.06.056_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000248868","article-title":"Retinoids in disorders of keratinization: their use in children","volume":"175","author":"Ruiz-Maldonado","year":"1987","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2018.06.056_bib55","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1517\/14656566.6.10.1725","article-title":"A review of acitretin, a systemic retinoid for the treatment of psoriasis","volume":"6","author":"Lee","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2018.06.056_bib56","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2133.2004.06181.x","article-title":"Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type","volume":"151","author":"Kopp","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1525-1470.2010.01084.x","article-title":"Generalized pustular psoriasis in childhood","volume":"27","author":"de Oliveira","year":"2010","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1525-1470.1998.tb01305.x","article-title":"Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases","volume":"15","author":"Juanqin","year":"1998","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib59","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1470.2009.00918.x","article-title":"Generalized pustular psoriasis in a 6-week-old infant","volume":"26","author":"Chao","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib60","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1525-1470.1995.tb00165.x","article-title":"Congenital erythrodermic psoriasis: case report and literature review","volume":"12","author":"Salleras","year":"1995","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630802132643","article-title":"Acitretin is a safe treatment option for infantile pustular psoriasis","volume":"19","author":"Ergin","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.06.056_bib62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.06.056_bib63","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00431-017-2985-x","article-title":"Treatment of severe psoriasis in children: recommendations of an Italian expert group","volume":"176","author":"Fortina","year":"2017","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaad.2018.06.056_bib64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2012.12.005","article-title":"Systemic treatments for severe pediatric psoriasis: a practical approach","volume":"31","author":"Marqueling","year":"2013","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2018.06.056_bib65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.06.056_bib66","first-page":"467","article-title":"Infliximab in pediatric Crohn's disease patients","volume":"2","author":"Baldassano","year":"2006","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jaad.2018.06.056_bib67","first-page":"881","article-title":"Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review","volume":"14","author":"Garber","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib68","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib69","first-page":"200","article-title":"Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab [in Spanish]","volume":"7","author":"Cobeta Garcia","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jaad.2018.06.056_bib70","first-page":"375","article-title":"Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Hagiyama","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib71","first-page":"888","article-title":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate","volume":"25","author":"Gwak","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1523-1747.ep12500067","article-title":"Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis","volume":"79","author":"Ashton","year":"1982","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib74","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib75","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ndt\/5.7.525","article-title":"Viral hepatitis in HBsAg-positive renal transplant patients treated with cyclosporin and steroids","volume":"5","author":"Sandrini","year":"1990","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.jaad.2018.06.056_bib76","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2893.2004.00515.x","article-title":"Restoration of immunity and reactivation of hepatitis B virus after immunosuppressive therapy in a patient with severe aplastic anaemia","volume":"11","author":"Dai","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jaad.2018.06.056_bib77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00007890-200108150-00009","article-title":"The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis","volume":"72","author":"Papatheodoridis","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2018.06.056_bib78","doi-asserted-by":"crossref","first-page":"O694","DOI":"10.1111\/1469-0691.12611","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome","volume":"20","author":"Mikulska","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jaad.2018.06.056_bib79","first-page":"18","article-title":"Inhibitory effect of cyclosporine A on hepatitis B virus replication in\u00a0vitro and its possible mechanisms","volume":"4","author":"Xia","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jaad.2018.06.056_bib80","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jaad.2018.06.056_bib81","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/BF01307747","article-title":"Activation of hepatitis C virus following immunosuppressive treatment","volume":"37","author":"Yoshiba","year":"1992","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaad.2018.06.056_bib82","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2796.1993.tb00734.x","article-title":"Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy","volume":"234","author":"Gruber","year":"1993","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaad.2018.06.056_bib83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0190-9622(99)80058-9","article-title":"Effects of acitretin on the liver","volume":"41","author":"Roenigk","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2018.06.056_bib85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"Perez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2018.06.056_bib86","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.3748\/wjg.v20.i13.3516","article-title":"Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease","volume":"20","author":"Sansone","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaad.2018.06.056_bib87","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"Vigano","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2018.06.056_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000439587","article-title":"Are anti-TNF-alpha agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature","volume":"232","author":"Di Nuzzo","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.06.056_bib89","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib90","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib91","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib92","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2005.05.043","article-title":"Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection","volume":"54","author":"Rokhsar","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib93","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2005.11.1035","article-title":"Etanercept therapy in two patients with psoriasis and concomitant hepatitis C","volume":"54","author":"De Simone","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib94","first-page":"645","article-title":"Tumour necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib95","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09546630310020470","article-title":"Etanercept therapy in patients with autoimmunity and hepatitis C","volume":"14","author":"Khanna","year":"2003","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.06.056_bib97","first-page":"4","article-title":"Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)","volume":"12","author":"Cecchi","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.06.056_bib98","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00124743-199906000-00015","article-title":"Etanercept and hepatitis C","volume":"5","author":"Pritchard","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib99","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib100","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2018.06.056_bib101","first-page":"406901","article-title":"Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography","volume":"2013","author":"Frider","year":"2013","journal-title":"Case Rep Hepatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib102","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib103","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.12612","article-title":"Hepatitis B virus reactivation after ustekinumab treatment","volume":"170","author":"Purnak","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib104","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjd.12120","article-title":"Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient","volume":"168","author":"Koskinas","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib105","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.06.056_bib106","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-4632.2011.04876.x","article-title":"Psoriasis treated with ustekinumab in a patient with hepatitis C","volume":"52","author":"Abuchar","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib107","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/jdv.14608","article-title":"Safety of secukinumab in hepatitis B virus","volume":"32","author":"Bevans","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1684\/ejd.2016.2939","article-title":"Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy","volume":"27","author":"Yanagihara","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib109","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1111\/jdv.14301","article-title":"Apremilast for a psoriasis patient with HIV and hepatitis C","volume":"31","author":"Reddy","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/108729100317696","article-title":"HIV-associated psoriasis","volume":"14","author":"Mallon","year":"2000","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.jaad.2018.06.056_bib111","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/archderm.1987.01660360050012","article-title":"Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome","volume":"123","author":"Duvic","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib112","first-page":"2191","article-title":"Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?","volume":"22","author":"Masson","year":"1995","journal-title":"J Rheumatol"},{"issue":"2 pt 2","key":"10.1016\/j.jaad.2018.06.056_bib113","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(94)70175-X","article-title":"The use of methotrexate for treatment of psoriasis in patients with HIV infection","volume":"31","author":"Maurer","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"3 pt 1","key":"10.1016\/j.jaad.2018.06.056_bib114","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0190-9622(97)70160-9","article-title":"Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine","volume":"37","author":"Tourne","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/0140-6736(92)90852-T","article-title":"Use of cyclosporin for psoriasis in HIV-positive patient","volume":"339","author":"Allen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.06.056_bib116","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib117","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archderm.1997.03890420043005","article-title":"Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection","volume":"133","author":"Buccheri","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib118","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/247553031117a00302","article-title":"Hydroxyurea for the treatment of psoriasis including in HIV-infected individuals: a review","volume":"17","author":"Lee","year":"2011","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.jaad.2018.06.056_bib119","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4103\/0378-6323.110807","article-title":"Long-term management of HIV\/hepatitis C virus associated psoriasis with etanercept","volume":"79","author":"Di Lernia","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2018.06.056_bib120","first-page":"413","article-title":"Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study","volume":"11","author":"Lee","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib121","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archderm.144.4.453","article-title":"Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus","volume":"144","author":"Mikhail","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib122","first-page":"1353","article-title":"Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection","volume":"34","author":"Linardaki","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib123","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4065\/75.10.1093","article-title":"Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis","volume":"75","author":"Aboulafia","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2018.06.056_bib124","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2018.06.056_bib125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jbspin.2006.05.012","article-title":"Use of infliximab to treat psoriatic arthritis in HIV-positive patients","volume":"74","author":"Sellam","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2018.06.056_bib126","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","article-title":"Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab","volume":"150","author":"Bartke","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib127","first-page":"869","article-title":"Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient","volume":"13","author":"Lindsey","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib128","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jdv.12531","article-title":"Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection","volume":"29","author":"Saeki","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.06.056_bib129","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/09546634.2011.579085","article-title":"Ustekinumab for the treatment of HIV psoriasis","volume":"23","author":"Paparizos","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.06.056_bib130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1164\/rccm.200701-057OC","article-title":"Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000","volume":"177","author":"Bennett","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2018.06.056_bib131","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Clinical practice. Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.06.056_bib132","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib133","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/09546634.2011.654107","article-title":"Detection and management of latent tuberculosis infections before biologic therapy for psoriasis","volume":"24","author":"Amerio","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.06.056_bib134","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/rheumatology\/37.10.1136","article-title":"Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy","volume":"37","author":"di Girolamo","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/40.3.341","article-title":"Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis","volume":"40","author":"Binymin","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2018.06.056_bib136","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2133.1971.tb02548.x","article-title":"Psoriasis, methotrexate and tuberculosis","volume":"84","author":"Smith","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib137","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4103\/0970-1591.42625","article-title":"Tuberculosis in renal transplant recipients","volume":"24","author":"Sundaram","year":"2008","journal-title":"Indian J Urol"},{"key":"10.1016\/j.jaad.2018.06.056_bib138","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/srin.2002.36445","article-title":"Mycobacterial infections in organ transplant recipients","volume":"17","author":"John","year":"2002","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.jaad.2018.06.056_bib139","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.06.056_bib140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.berh.2006.06.002","article-title":"Problems encountered during anti-tumour necrosis factor therapy","volume":"20","author":"Desai","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib141","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.06.056_bib142","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2174\/138945010790310009","article-title":"How to manage the infectious risk under anti-TNF in inflammatory bowel disease","volume":"11","author":"Culver","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jaad.2018.06.056_bib143","doi-asserted-by":"crossref","first-page":"e000044","DOI":"10.1136\/rmdopen-2014-000044","article-title":"The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region","volume":"1","author":"Mariette","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2018.06.056_bib144","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.160420","article-title":"Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"43","author":"Kay","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.06.056_bib145","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","article-title":"The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection","volume":"167","author":"Tsai","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221832214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:48:28Z","timestamp":1759272508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221832214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S019096221832214X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.056","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis: Which therapy for which patient","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(18)32921-9","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}